Covid Inquiry: What have we learnt so far?
The first phase of the Covid Inquiry has come to an end. What have we learnt over the past six weeks?
Similar Posts
Baby formula recalled over bacteria contamination fears
Reckitt are recalling batches of Nutramigen powders after finding bacteria in an “isolated overseas sample”.
11 Holiday Items That Are Secretly Dangerous For Pets
The holidays mark a fun occasion for people to decorate their homes, cook special dishes, exchange gifts with loved ones and otherwise appreciate the many joys life has to offer. For pet owners, however, the season brings a host of challenges and potential issues to pay attention to. “The winter holidays are one of the…
Bayer’s new CEO plans to cut management jobs in prelude to overhaul | Reuters News Agency
Business & FinanceHealth 15 September 2023, 1:53 pm 1 minute Reuters exclusively reported that Bayer’s (BAYGn.DE) new CEO plans to cut management jobs to speed up decision-making as a first step to overhaul the embattled German industrial group, which is facing investor pressure to break up. Market Impact Anderson has been tasked with reviving Bayer’s…
Asia’s year in review: Who had it good — and who had it bad — in 2023
Curtis S. Chin, a former U.S. ambassador to the Asian Development Bank, is managing director of advisory firm RiverPeak Group. Jose B. Collazo is an analyst focusing on the Indo-Pacific region. Follow them on X at @CurtisSChin and @JoseBCollazo. As 2023 comes to a close, we take a look at the year that was in…
Catalent’s Indiana plant to make Novo’s Wegovy weight-loss drug | Reuters News Agency
Health 25 August 2023, 6:39 pm 1 minute Reuters exclusively reported that Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but…
Cystic fibrosis: The miracle drugs priced out of reach
Regulators around the world have questioned the high price set by Vertex Pharmaceuticals.
